Boehringer Ingelheim

For Healthcare Professionals

Logout

Boehringer Ingelheim

Boehringer Ingelheim

Boehringer Ingelheim

Therapeutic Area
Therapeutic Area

At Boehringer Ingelheim we are driven by the desire to serve mankind by improving human and animal health. As a successful, family owned company we plan in generations. We work together globally and with integrity. Our Focus articulates who we are and what we strive for, how we work and what we want to achieve.

Section Overview

Therapeutic Area

Section Overview

Cardiovascular

Metabolic

Inflammation

Respiratory
Products
Products

Boehringer Ingelheim is a research-driven group of companies dedicated to the discovery, development, manufacture and marketing of innovative health care products.

See all products

Products

See all products
Resources
Contact
Logout

Boehringer Ingelheim

Empagliflozin

Iinagliptin

Format

Sort by

Reset all filters

Prof. Roger Chen on Empagliflozin as CRM Medication

3:39

Prof. Roger Chen on Empagliflozin as CRM Medication

Watch now Opens in new tab

Prof. Roger Chen on Early Initiation of Empagliflozin

1:40

Prof. Roger Chen on Early Initiation of Empagliflozin

Watch now Opens in new tab

Prof. Melanie Davies on Empagliflozin as CRM Medication

1:09

Prof. Melanie Davies on Empagliflozin as CRM Medication

Watch now Opens in new tab

Prof. Melanie Davies - T2D Guidelines Recommendation

1:14

Prof. Melanie Davies - T2D Guidelines Recommendation

Watch now Opens in new tab

Prof. Melanie Davies on Early Initiation of Empagliflozin

1:00

Prof. Melanie Davies on Early Initiation of Empagliflozin

Watch now Opens in new tab

Experts Video Prof. Zieroth Safety in HF with T2D

1:43

Expert's Video Prof. Zieroth Safety in HF with T2D

Watch now Opens in new tab

Pagination

Load More

Home
Metabolic
Empagliflozin

Sitemap

Therapeutic Area

Resources
- Videos
- Clinical studies

BI logo

Privacy
Terms of use
Sitemap
Contact

Copyright © 2025 Boehringer Ingelheim (Philippines), Inc. All rights reserved. Use of this Site is subject to the Terms of Use and Privacy Statement. Prepared June 2025